Edition:
United Kingdom

Profile: Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

6.35USD
23 May 2019
Change (% chg)

$-0.01 (-0.16%)
Prev Close
$6.36
Open
$6.27
Day's High
$6.39
Day's Low
$6.20
Volume
256,821
Avg. Vol
276,258
52-wk High
$17.05
52-wk Low
$5.89

Dynavax Technologies Corporation (Dynavax), incorporated on November 6, 2000, is a clinical-stage immunotherapy company focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The Company's product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. The Company's pipeline of product candidates includes HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

HEPLISAV-B

The Company's product candidate HEPLISAV-B is an investigational adult hepatitis B vaccine. HEPLISAV-B combines 1018, a TLR9 agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). HEPLISAV-B is in Phase III of its clinical trials.

AZD1419

AZD1419 is being developed for the treatment of asthma pursuant to a collaboration with AstraZeneca AB (AstraZeneca). AZD1419 is designed to change the basic immune response to environmental allergens, such as house dust and pollens, leading to prolonged reduction in asthma symptoms by converting the response from one primarily mediated by type-2 helper thymus (T) cells to type-1 helper T cells. AZD1419 is in Phase II of its clinical trials.

SD-101

SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. By targeting TLR9 in both the early and late endosomes of plasmacytoid dendritic cells, SD-101 is intended to stimulate multiple mechanisms of tumor killing. SD-101 is indicated for Melanoma, Head and Neck Squamous Cell Carcinoma and Multiple Malignancies. For melanoma, and head and neck squamous cell carcinoma, SD-101 is being tested in Phase II, and for other Multiple Malignancies, it is being tested in Phase I.

DV281

DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV281 is similar in biological activity and mechanism of action to SD-101, but has been optimized for administration as an aerosol. DV281 targets non-small cell lung cancer.

The Company competes with Aduro Biotech, Inc., Idera Pharmaceuticals, Inc., Immune Design Corp. and Checkmate Pharmaceuticals, Inc.

Company Address

Dynavax Technologies Corp

2929 7th St Ste 100
BERKELEY   CA   94710-2753
P: +1510.8485100
F: +1510.8481327

Company Web Links